Supreme Court Upholds Public Interest in Roche v. Natco SMA Drug Patent Dispute

In a landmark decision with profound implications for pharmaceutical patent law and public health in India, the Supreme Court has cleared the path for Natco Pharma to launch a generic version of a life-saving drug for Spinal Muscular Atrophy (SMA), dismissing an appeal from Swiss pharmaceutical giant F. Hoffmann-La Roche.

NEW DELHI – The Supreme Court of India, in a significant ruling, has declined to interfere with a Delhi High Court order that refused to grant an interim injunction against Natco Pharma, effectively allowing the Indian generic drug manufacturer to launch its version of Risdiplam. The decision underscores the judiciary's increasing tendency to weigh public interest and access to affordable medicine heavily against statutory patent rights, particularly in cases involving rare diseases with exorbitant treatment costs.

A bench led by Justice P.S. Narasimha dismissed Roche's special leave petition, which sought to restrain Natco from launching its generic product while the primary patent infringement suit is pending. The apex court directed that the underlying suit for a permanent injunction before the Delhi High Court's single-judge bench be decided expeditiously, clarifying that those proceedings should remain uninfluenced by any interim observations.

This decision affirms the lower court's rationale and signals a pivotal moment in the ongoing tension between intellectual property protection and the right to health in India.

The Core of the Dispute: A Life-Saving Drug and a Species Patent

The legal battle centers on Risdiplam, an oral therapy for Spinal Muscular Atrophy (SMA), a rare and debilitating genetic disorder, prescribed for patients aged two months and older. Roche markets its formulation under the brand name Evrysdi and claims a valid "species patent" for Risdiplam, the drug's active pharmaceutical ingredient (API). The company currently imports and sells Evrysdi in India at a maximum retail price of approximately ₹6 lakh per bottle.

Roche contended that its patent, titled “compounds for treating spinal muscular atrophy,” was developed after years of extensive research and is distinct from its earlier "genus patent." Senior Counsel N.K. Kaul, representing Roche before the Supreme Court, argued vehemently that Risdiplam was “neither disclosed nor rendered obvious by its earlier genus patent” and that the company holds valid patents for the drug in over sixty countries.

The central pillar of Roche’s legal strategy was to assert the primacy of its statutory rights. Kaul argued that "public interest considerations cannot override statutory patent rights merely because a rival product is cheaper." This argument posits that allowing a generic competitor to enter the market based on price alone would undermine the entire patent system, which is designed to reward and incentivize costly and time-consuming pharmaceutical innovation.

The Public Interest Counterweight: Delhi High Court's Foundational Reasoning

The Supreme Court's refusal to intervene upholds the foundational reasoning laid out by a single-judge bench of the Delhi High Court in March. While rejecting Roche's initial plea for an interim injunction, the High Court had made a crucial observation that has now been tacitly endorsed by the nation's highest court.

The High Court noted, “a drug which is the only one available for treatment in India, for a rare disease, its availability to the public at large at very economical and competitive prices, is a material factor which a court will consider at the time of dealing with an application for interim injunction.”

This statement encapsulates the judiciary's balancing act. In the context of an interim injunction—a discretionary, equitable remedy—the court must weigh the "balance of convenience" and the potential for "irreparable harm." The High Court, and now the Supreme Court, found that the potential harm to the public from the lack of access to an affordable life-saving medicine outweighed the potential commercial harm to the patent holder.

Following the High Court's decision, Natco Pharma announced its immediate launch of the generic Risdiplam at a price of ₹15,900 per bottle. This represents a staggering price reduction of over 95%, a figure that was a cornerstone of Natco's submission that it would manufacture the drug locally and ensure broad accessibility.

Legal and Industry Implications: A Chilling Effect or a Public Health Victory?

This ruling is poised to have significant ripple effects across the pharmaceutical and legal sectors. For patent holders, particularly multinational pharmaceutical corporations, the decision may be viewed as a dilution of patent protection in India. It reinforces the perception that Indian courts may be reluctant to grant pre-trial injunctions against generic manufacturers, especially when a substantial public interest component is involved. This could influence investment and litigation strategies for companies launching innovative, high-cost medicines in the Indian market.

Conversely, for public health advocates and the generic pharmaceutical industry, the decision is a resounding victory. It strengthens the legal precedent that access to medicine is a compelling public interest that can, at the interim stage, supersede a patentee's prima facie rights. This aligns with the broader objectives of Indian patent law, particularly Section 83 of the Patents Act, 1970, which states that patents are not granted merely to enable patentees to enjoy a monopoly, but to ensure that the inventions are worked in India on a commercial scale to the fullest extent that is reasonably practicable without undue delay and are available to the public at reasonably affordable prices.

Legal experts suggest that while the final infringement suit is yet to be decided on its merits, the denial of an injunction at this stage is a critical strategic win for Natco. It allows the generic drug to enter the market, establish a patient base, and demonstrate the tangible public benefit of affordable access, which could indirectly influence the final adjudication.

Roche, in its defense, highlighted its patient access initiatives, stating that it had launched a Compassionate Use Program (CUP) in 2020, providing the drug free of cost to 52 SMA patients. The company also noted that approximately 300 patients have benefited from Evrysdi since its 2021 launch. However, these numbers pale in comparison to the potential patient population for a rare disease, a fact that likely weighed on the courts' assessment of the public interest dimension.

As the case returns to the Delhi High Court for a final decision on the merits of the patent infringement claim, the legal community will be watching closely. The outcome will not only determine the fate of Risdiplam in India but will also continue to shape the delicate and often contentious balance between innovation, intellectual property, and the fundamental right to health.